ARS Pharmaceuticals Announces U.S. Availability of neffy® …
网页2 天之前 · Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnectSAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc ...
ARS Pharmaceuticals Announces U.S. Availability of neffy® …
网页2 天之前 · ARS Pharmaceuticals has also submitted a supplemental New Drug Application (sNDA) to the FDA for the use of neffy 1 mg in pediatric patients weighing 15 to 30 kg (33 to 66 lbs.), further ...
ARS Pharmaceuticals Announces U.S. Availability of neffy® …
网页2 天之前 · ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of …
ARS Pharmaceuticals, Inc. (SPRY) Stock Price, News, Quote
网页Find the latest ARS Pharmaceuticals, Inc. (SPRY) stock quote, history, news and other vital information to help you with your stock trading and investing.
ARS Pharmaceuticals, Inc. (SPRY) Latest Stock News & Headlines
网页Get the latest ARS Pharmaceuticals, Inc. (SPRY) stock news and headlines to help you in your trading and investing decisions.
Press Releases - ARS Pharmaceuticals
网页2024年4月30日 · ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
Silverback Therapeutics and ARS Pharmaceuticals Announce …
网页2022年7月21日 · SEATTLE and SAN DIEGO – July 21, 2022 – Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS Pharmaceuticals, Inc. (“ARS”) today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction.
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
网页2022年11月8日 · ARS Pharmaceuticals Closes Merger with Silverback Therapeutics. Over $280 Million in Combined Cash and Securities and at least Three Years Operating Runway to Support Launch and Commercialization of neffy® in the U.S., if Approved.
ARS Pharma launches neffy epinephrine nasal spray in U.S.
网页ARS Pharmaceuticals (NASDAQ:SPRY) has launched neffy, an epinephrine nasal spray, in the U.S. market. The drug won U.S. FDA approval in August for anaphylaxis in individuals who weigh at least 66 ...
ARS Pharmaceuticals updates manufacturing agreement terms
网页1 天前 · In other recent news, ARS Pharmaceuticals has made significant progress with the FDA approval of Neffy, a needle-free epinephrine treatment for Type I Allergic Reactions. The company has also ...